Merck’s first quarter results drew a positive market reaction, reflecting operational resilience despite a 1.6% ...

CHICAGO — In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in ...

At the trial’s first pre-specified interim analysis, Keytruda before surgery (neoadjuvant), then continued after surgery (adjuvant) in combination with standard of care (SOC), RT with or without ...

Keytruda is designed to enhance the immune system's ability to detect and combat tumour cells. This humanised monoclonal antibody prevents PD-1 from interacting with its ligands, PD-L1 and PD-L2 ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has been approved by the US Food and Drug Administration (FDA) to treat a new ...

MSD’s Keytruda is being studied in more than 1,600 trials across various cancers and treatment settings. Credit: Katherine Welles/Shutterstock. MSD has received US Food and Drug Administration (FDA) ...

The trial was not designed to isolate the effect of KEYTRUDA in each phase (neoadjuvant or adjuvant) of treatment. The major efficacy outcome measure was event-free survival (EFS) by BICR defined as ...

Keytruda is Merck's best-selling drug, generating more than $7 billion in revenue in the first quarter. Merck ( MRK ) has received the go-ahead to expand use of its blockbuster cancer drug, Keytruda.

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. | Merck & Co.’s Keytruda has ...

RAHWAY, N.J., June 13, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® ...

FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, ...

Keytruda generated sales of $7.21 billion in the first quarter of 2025, rising 6% year over year. Our model estimates for Keytruda suggest a CAGR of 5.4% over the next three years. MRK’s Price ...